280 related articles for article (PubMed ID: 7684865)
1. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
Porter AT; McEwan AJ
Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
[TBL] [Abstract][Full Text] [Related]
2. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
[No Abstract] [Full Text] [Related]
3. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
4. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
De Ruysscher D; Spaas P; Specenier P
Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
6. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
Kan MK
Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
Kiselev EN; Korytova LI; Karelin MI
Vopr Onkol; 2005; 51(6):689-91. PubMed ID: 17037036
[TBL] [Abstract][Full Text] [Related]
8. Systemic radionuclide therapy of bone metastases with strontium-89.
Porter AT; Davis LP
Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
[TBL] [Abstract][Full Text] [Related]
9. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
10. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with strontium-89 in prostatic and breast cancer patients.
Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.
Di Lorenzo G; Autorino R; Ciardiello F; Raben D; Bianco C; Troiani T; Pizza C; De Laurentiis M; Pensabene M; D'Armiento M; Bianco AR; De Placido S
Oncol Rep; 2003; 10(2):399-404. PubMed ID: 12579279
[TBL] [Abstract][Full Text] [Related]
13. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone.
Porter AT
Eur Urol; 1994; 26 Suppl 1():20-5. PubMed ID: 7537665
[TBL] [Abstract][Full Text] [Related]
14. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
Porter AT; McEwan AJ; Powe JE; Reid R; McGowan DG; Lukka H; Sathyanarayana JR; Yakemchuk VN; Thomas GM; Erlich LE
Int J Radiat Oncol Biol Phys; 1993 Apr; 25(5):805-13. PubMed ID: 8478230
[TBL] [Abstract][Full Text] [Related]
16. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
Altman GB; Lee CA
Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
[TBL] [Abstract][Full Text] [Related]
17. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
[TBL] [Abstract][Full Text] [Related]
18. [Strontium-89 for bone metastases from prostate cancer: an update].
Zhao WW; Xie P; Deng HF
Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone.
McEwan AJ; Amyotte GA; McGowan DG; MacGillivray JA; Porter AT
Eur Urol; 1994; 26 Suppl 1():26-31. PubMed ID: 7537666
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
Haesner M; Buchali K; Pink V; Lips H
Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
